# Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)

> **NCT00261365** · PHASE1,PHASE2 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 80 (estimated)

## Conditions studied

- Unresectable Stage III or IV Malignant Melanoma

## Interventions

- **DRUG:** Ipilimumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT00261365
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2007-10
- **Final completion:** 2007-10
- **Target enrollment:** 80 (ESTIMATED)
- **Last updated:** 2016-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00261365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00261365, "Phase II Study to Determine Predictive Markers of Response to BMS-734016 (MDX-010)". Retrieved via AI Analytics 2026-07-10 from https://api.ai-analytics.org/clinical/NCT00261365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*